Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?

被引：0
|
作者：
Kadri Altundag
机构：
[1] MKA Breast Cancer Clinic,
来源：
Journal of Neuro-Oncology | 2017年 / 135卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：639 / 639
相关论文
共 50 条
  • [31] Treatment of HER2 positive stage 4 breast cancer: When to stop anti-HER2 agents.
    Kamada, Yoshihiko
    Takigami, Naoko
    Uehara, Kanou
    Tamaki, Kentaro
    Tamaki, Nobumitsu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    Mora-Rufete, A.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 639 - 645
  • [33] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [34] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [35] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [36] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [37] Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts
    Barbieri, E.
    Piacentini, F.
    Dieci, M. V.
    Ficarra, G.
    Bettelli, S.
    Conte, P.
    Guarneri, V.
    CANCER RESEARCH, 2011, 71
  • [38] HER2 positive gastric cancer: Who benefits from HER2 targeted therapy?
    Kolbe, K.
    Haffner, I.
    Schierle, K.
    Maier, D.
    Geier, B.
    Luber, B.
    Kretzschmar, A.
    von Weikersthal, Fischer L.
    Ahlborn, M.
    Riera, J.
    Rau, B.
    Siegler, G.
    Fuxius, S.
    Decker, T.
    Wittekind, C.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 156 - 157
  • [39] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
  • [40] Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients
    Arslan, U. Y.
    Turker, I.
    Aksoy, S.
    Oksuzoglu, B.
    Helvaci, K.
    Ozdemir, N. Yildirim
    Uyeturk, U.
    Sonmez, O. Uysal
    Budakoglu, B.
    Zengin, N.
    JOURNAL OF BUON, 2013, 18 (03): : 585 - 593
12345